The Stanford spinout has collected series A funding from investors including Johnson & Johnson and Osage University Partners.
Hyalex Orthopaedics, a US-based medical device spinout of Stanford University, raised $16m in series A capital on Wednesday from backers including pharmaceutical firm Johnson & Johnson.
The corporate, which invested through its investment unit Johnson & Johnson Innovation – JJDC, was joined by Canaan Partners, which led the round, and spinout-focused investment firm Osage University Partners.
Hyalex is commercialising synthetic biomaterial that mimics the structure and function of the hyaline cartilage, which lines articulating joints such as the shoulder, knee…
